Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557453 | 0.90 | HPGD (0.68) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557603 | 0.89 | HPGD (0.72) | MAPTTP53THRBHPGDLMNA | |
| SCHEMBL16557432 | 0.86 | MAPT (0.59) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557447 | 0.85 | MAPT (0.67) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557445 | 0.83 | SMN1; SMN2 (0.62) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557449 | 0.83 | MAPT (0.65) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL16557436 | 0.83 | HPGD (0.63) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557442 | 0.83 | LMNA (0.56) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557439 | 0.83 | TP53 (0.67) | MAPTTP53THRBSMN1; SMN2HPGD | |
| SCHEMBL16557438 | 0.82 | MAPT (0.56) | MAPTTP53THRBSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | MAPT 4311/4885TP53 4037/4885THRB 3031/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | MAPT 4311/4885TP53 4037/4885THRB 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.